Objective Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the feasibility of developing tumor diagnosis ligands superior to radioiodinated PHY. Methods New phenoxyquinazoline derivatives were designed with various side chains introduced to the 6th position of PHY. The IC 50 values of the new derivatives to interrupt EGFR-TK phosphorylation were evaluated and compared to well-known EGFR-TK inhibitors. Tumor uptake studies of the new 125 I-labeled derivatives were conducted with A431 tumor-bearing mice. Selectivity and binding characteristics were analyzed by in vitro blocking studies and a binding assay. Furthermore, SPECT/CT scans were performed using A431 tumor-bearing mice. Results Six quinazoline derivatives were designed and synthesized, and among these, 6a-d were found to have relatively high EGFR-TK inhibitory potency. In tumor uptake studies, [ 125
Introduction
Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways that regulate fundamentally important cellular functions. EGFR consists of an outer membrane EGF binding site and an inner membrane tyrosine kinase domain (EGFR-TK). EGFR-TK phosphorylation is stimulated by epidermal growth factor (EGF) or transforming growth factor a (TGFa) binding to the extracellular ligand-binding domain of EGFR and subsequent receptor dimerization. The intracellular tyrosine residues then undergo phosphorylation, which is followed by second messenger signaling and subsequent downstream events that lead to cellular proliferation, differentiation, motility, adhesion, and apoptosis [1, 2] . EGFR is often overexpressed in cancers [3] [4] [5] [6] , thus inhibition of EGFR-TK as a target for cancer chemotherapy has proven to be effective in both preclinical and clinical settings. EGFR-TK represents an attractive target for the development of new antitumor agents [7, 8] . Among the EGFR-TK inhibitors used or tested clinically as antitumor agents are the quinazoline derivatives ZD1839 (Astra-Zeneca) [9, 10] and OSI774 (Pfizer) [10, 11] . One of the most potent compounds in the EGFR-TK inhibitor series is the quinazoline derivative PD153035 [12, 13] , which exhibits well-defined selectivity and tremendously high affinity for EGFR-TK (K i : 5 pM) coupled with remarkable cytotoxicity against several types of tumors in vitro such as the A431 epidermoid carcinoma cell line (IC 50 : 29 pM). In an effort to develop new cancer diagnostic agents, several PET and SPECT ligands have been synthesized and evaluated for imaging of EGFR-TK. The feasibility of targeting EGFR for tumor imaging has been experimentally demonstrated using 18 F or 11 C-labeled EGFR-TK inhibitors [14] [15] [16] [17] [18] [19] [20] ; however, these labeled compounds were also observed to produce high radioactivity in the blood and peripheral tissues. Therefore, tumor images with these radioligands were affected by the radioactivity in peripheral tissues a short time after injection.
We have previously synthesized and evaluated several radioiodinated quinazoline derivatives as new EGFR-TK imaging ligands (m-IPQ: 4-(3-Iodoanilino)-6,7-diethoxyquinazoline (IC 50 value; 50.5 ± 3.5 nM), PHY: 4-(3-Iodophenoxy)-6,7-diethoxyquinazoline (IC 50 value; 49.0 ± 7.2 nM), Fig. 1 ) [21, 22] . In vivo stability of 125 I]PHY was not good enough for in vivo molecular imaging probe. Therefore, we have been investigated the new EGFR-TK imaging probes superior to PHY in tumor accumulation and retention by the ligand structure modification.
In this paper, several new quinazoline derivatives were designed on the basis of essential requirements for radiophamaceuticals and structure-activity relationships. New 125 I-labeled derivatives with various side chains introduced into the 6th position of PHY were synthesized, and biological studies with these compounds were carried out including analysis of SPECT/CT images. From these results, the new radioiodinated derivatives were evaluated for their use in SPECT tumor imaging.
Materials and methods

[ 125 I]NaI and [
32 P]ATP were purchased from Tokyo Biomedical (Tokyo, Japan) and Muromachi Yakuhin (Tokyo, Japan), respectively. All other chemicals were of reagent grade and were purchased from Sigma-Aldrich Japan (Tokyo, Japan), Nacalai Tesque (Kyoto, Japan), Wako Pure Chemical Industry (Osaka, Japan) or Tokyo Chemical Industry (Tokyo, Japan). 4-(3-Iodophenoxy)-6,7-diethoxyquinazoline (1, PHY) was synthesized according to our previous paper [22] . 4-(3-chloropropyl) morpholine and 1-(3-chloropropyl)-4-methylpiperazine were synthesized by the method of Adams et al. [23] . The HPLC system employed included a M-600 pump, a Lambda-Max 481 ultraviolet detector (Waters, MA), a 170 NaI radioactivity detector (Beckman, CA), and a 5 C 18 -AR column (10 9 250 mm, Nacalai Tesque, Kyoto, Japan). Male ddY mice and balb/c nude mice were obtained from Japan SLC Inc. (Shizuoka, Japan). Animals were housed with ad libitum access to food and drinking water for at least one week before initiating experiments. Animals were housed and experiments were performed according to guidelines stipulated by the Osaka University of Pharmaceutical Sciences Animal Care and Use Committee.
6-Hydroxy-7-ethoxyquinazolin-4(3H)-one (2)
A mixture of 6,7-diethoxyquinazolin-4(3H)-one (9.2 g, 39.4 mmol) and L-methionine (7.05 g, 47.3 mmol) was dissolved in methanesulfonic acid (60 mL) and heated to 100°C for 4 h. The mixture was cooled to room temperature, poured onto a mixture (200 mL) of ice/water, and neutralized by the addition of aqueous sodium hydroxide solution (40 %) resulting in precipitation of a white deposit. This product was collected by filtration using a sintered glass funnel, washed with water, and was used without further purification. 6-Acetoxy-7-ethoxyquinazoline 4(3H)-one (3) A stirred suspension of 6-hydroxy-7-methoxyquinazolin-4(3H)-one (2, 7.3 g, 35.4 mmol) in acetic anhydride (40 mL), pyridine (6.0 mL) and N,N-dimethyl-4-aminopyridine (100 mg, 0.819 mmol) was heated to 100°C for 6 h. Crushed ice/water solution (150 mL) was added to the reaction mixture, and the resulting white precipitate was filtered and washed with water.
Yield 4-Chloro-6-acetoxy-7-ethoxyquinazoline-6-yl acetate (4) A stirred solution of 7-ethoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate (3, 2.0 g, 22.7 mmol) and N,N-diethylaniline (28.5 mL) in phosphoryl chloride (30 mL) was immersed in a preheated oil bath at 100°C for 30 min. The reaction mixture was stirred for a further 30 min at 80°C. The phosphoryl chloride was removed, and the crude material was triturated with abs. toluene (3 9 30 mL). Crushed ice/water was added (200 mL) to the reaction mixture, and the light brown precipitate was filtered and washed with ice water (100 mL). The brownish precipitate was air-dried.
Yield 7-Ethoxy-6-hydroxy-4-(3 0 -iodophenoxy)quinazoline (5) 3-Iodophenol (6.0 g, 27.3 mmol) and KOH (6.0 g, 27.3 mmol) were heated at 50°C, and then 4 (0.5 g, 2 mmol) was added slowly over 10 min. After cooling, the reaction mixture was dissolved in CHCl 3 (50 mL), the solution was washed with 100 mL of water, and then the organic layer was dried with Na 2 SO 4 and evaporated to give an oily residue that was purified by silica gel column chromatography (MeOH/CHCl 3 = 1/10) to afford the desired compound.
Yield 125 I]6a-d was collected, and the solvent was removed in vacuo. Retention times, radiochemical yields, and radiochemical purities of the tracers were measured by HPLC.
Cell culture
A431 human carcinoma cell line was cultured in serumsupplemented Dulbecco's modified Eagle's medium (DMEM) containing 10 % heat-inactivated fetal bovine serum and penicillin/streptomycin mixed solution at 37°C. The cells were split weekly in a 1:10 ratio using trypsin/ EDTA. They were then transferred to 100 mm cell culture dishes and allowed to grow until reaching confluence (about 0.5 million cells). Subsequently, the cells were detached using either trypsin/EDTA (0.25 %, 1.0 mL) or by scraping with a cell scraper into DMEM when they reached sub confluence. NALM6 leukemia cell line [24] as a nonadherent cell was cultured in DMEM containing 10 % heatinactivated fetal bovine serum and penicillin/streptomycin mixed solution at 37°C. The cells were split weekly into a 1:10 ratio. They were then transferred to culture flask and allowed to grow until about 0.5 million cells were obtained.
Measurement of inhibitory potency against EGFR-TK
The inhibitory potency of the new derivatives against EGFR-TK was measured using a Signa TECT Ò Protein Kinase Assay System (Promega, WI) according to the protein tyrosine kinase assay protocol of the attached document. The EGF receptor used was an immunopurified receptor from human A431 cells (Promega, WI). The substrate used was based on a portion of biotinylated protein tyrosine kinase selective peptide. EGF receptors (1 lg of protein, 5 lL), sodium vanadate (2.5 mM, 2.5 lL), biotinylated protein tyrosine kinase selective peptide (2.5 mM, 2.5 lL) and the dissolved test compound in water including 1 % DMSO (desired concentration, 7.5 lL) were added to the PTK assay 5X buffer (5 lL), and the mixture was preincubated at 30°C for 5 min. Next, [ 32 P]ATP (0.5 mM ATP, 18.5 kBq, 2.5 lL) was added to the reaction mixture. The reaction was allowed to proceed for 10 min at 30°C and then was stopped by the addition of guanidine hydrochloride solution (7.5 M, 13 lL). Each reaction mixture (12.5 lL) was spotted onto a biotin capture membrane. After all of the samples had been spotted, they were washed and rinsed as follows: 1 time for 30 s with 200 mL of 2 M NaCl, 3 times for 2 min each with 200 mL of 2 M NaCl, 4 times for 2 min each with 200 mL of 2 M NaCl in 1 % H 3 PO 4 , and 2 times for 30 s each with 100 mL of deionized water. The biotin capture membranes were dried on a piece of aluminum foil under a heat lamp for 5-10 min. The radioactivity trapped on the biotin capture membranes was counted with a liquid scintillation counter in 10 mL of scintillation fluid. The IC 50 values were determined from sigmoid curves of the percent inhibition of [ 32 P]ATP radioactivity.
Tumor uptake studies of radioiodinated ligands using tumor-bearing mice A suspension of 1 9 10 7 A431 cells in 0.1 mL of medium was inoculated subcutaneously in male balb/c nude mice (4 weeks old, 20-25 g, n = 3). After approximately 2 weeks, when the solid tumor had grown to optimal size, the mice were used for tumor uptake studies. [
125 I]6a-d (37 kBq, 74 TBq/mmol) in 0.1 mL of saline was injected intravenously into tumor-bearing mice via the lateral tail vein. At 1 or 24 h after administration, the animals were sacrificed. Samples of tumor were excised and weighed. Radioactivity was measured using a well-type NaI(Tl) scintillation gamma counter. The results were expressed in terms of percentage of injected dose per gram of tumor.
Biodistribution of the [
125 I]PYK using normal and tumor-bearing mice [ 125 I]PYK (37 kBq, 74 TBq/mmol) in 0.1 mL saline was injected intravenously into ddY male mice (5 weeks old, 25-30 g, n = 4) via the lateral tail vein. At the desired time (5 min-24 h) interval after administration, the animals were sacrificed by decapitation. Samples of blood and tissues of interest were excised and weighed. Radioactivity was measured using a well-type NaI(Tl) scintillation gamma counter. The results were expressed in terms of percentage of injected dose per gram of blood or tissue.
Next, biodistribution studies of [ 125 I]PYK using A431 bearing balb/c nude mice (6 weeks old, 20-25 g, n = 4) were performed. The animals were euthanized 1, 6, 12 or 24 h after injection of the radioligands (37 kBq, 74 TBq/mmol in 0.1 mL saline), and the distributions were studied as described above. . The animals were sacrificed 24 h after injection of the radioligands, and the ligand distribution was studied as described above. The differences between non-treatment and pretreatment data were examined by Student's paired t tests.
Binding assay of [ 125 I]PYK
Assays were carried out as described in the previous section. Crude P 2 membrane fractions (A431or NALM6, 0.1 mg of protein, 10 lL) and [
125 I]PYK (1-300 nM, 100 lL, 0.74 kBq) were used. Non-specific binding was determined in the presence of PD153035 (10 lM). Specific binding was defined as the difference between the total and non-specific binding. Scatchard plot analysis of the saturation binding data was used to determine the equilibrium dissociation constant (K d ) and the maximal number of binding sites (B max ).
SPECT/CT imaging
The mice underwent SPECT/CT studies when A431 tumors had grown to optimal size (approximately 2 weeks after inoculation).
125
I gamma camera imaging and image processing were performed using a small-animal imaging system with pinhole collimation (aperture diameter = 1 mm, focal length = 9 cm) and a 15-to 45 keV photo peak energy window (PET/SPECT/CT FX system, Gamma Medica Ideas). The A431 tumor-bearing mice were injected with approximately 14.8 MBq of [ 125 I]PYK via the tail vein under isoflurane anesthesia. 24 h after injection, SPECT scans were performed at 64 projections over 360°(ROR = 4.5 cm, 60 s/projection). Reconstructed data from SPECT and CT were visualized and coregistered using AMIRA 3.1.
Results
Chemical synthesis
4-(3-Iodophenoxy)-6,7-diethoxyquinazoline derivatives were designed and synthesized by the reaction scheme outlined in scheme 1. 4-Chloro-6,7-diethoxyquinazoline (1) was synthesized according to a modified procedure of Van Brocklin et al. [25] . Treatment with methanesulphonic acid in the presence of methionine dealkylated only the ethoxy group at the 6th position of 1. The resulting free phenolic function of compound 2 was protected using acetic anhydride in the presence of pyridine to give compound 3. Halogenation yielding the 4-chloro-compound 4 was performed with phosphoryl chloride according to the method of Rewcastle et al. [26] . Subsequently, reaction of 4 with 3-iodophenol in the presence of KOH yielded compound 5 following the method of Morley et al. [27] . Next, various side chains were introduced to the 6th position of the quinazoline (6a-f, 38.1-88.6 %).
Inhibitory potency of new derivatives against EGFR-TK
The inhibitory potency of new phenoxyquinazoline derivatives against EGFR-TK in A431 cell membranes was measured as the inhibition of EGFR phosphorylation by [ Table 1 . Among the newly synthesized derivatives, 6a and 6b were found to have high potency (IC 50 ; 12.0 ± 3.9, 16.5 ± 1.8 nM, respectively), slightly lower than that of PD153035 (IC 50 ; 4.9 ± 1.29 nM). 6c and 6d were determined to possess comparable values to PHY (IC 50 ; 41.5 ± 4.1, 113 ± 7.0 nM, respectively). On the other hand, 6e and 6f were found to have low inhibition of EGFR-TK (IC 50 ; [500 nM, respectively). From these results, radiolabeling of 6a-d was performed for further evaluation. The radiochemical purities of these tracers were 99 %, and the specific activities were estimated to be approximately 74 TBq/ mmol in theory since tin precursors were used and labeling was carried out under non-carrier-added conditions.
Tumor uptake studies of the radioiodinated ligands In in vivo tumor uptake studies with A431 tumor-bearing mice (Fig. 2) , the accumulation of [ administration and summarized in Table 3 . [ 125 I]PYK was transported well into various organs and disappeared slowly from the blood. In the liver highest uptake and rapid clearance were observed. The lungs, kidney, heart, pancreas, spleen, and brain uptakes were similar pattern to that of the liver. Furthermore, the increase in [
125 I]PYK uptake in the stomach and thyroid as deiodination parameters were not found. Therefore, it is suggested the good stability of Discussion EGFR-TK activation is involved in the proliferation, invasion, metastasis, angiogenesis, and suppression of apoptosis of cancer cells [1, 2] . Therefore, EGFR-TK is an attractive molecular target for tumor diagnosis. Several radiolabeled quinazoline derivatives that have high inhibitory potency against EGFR-TK have been studied for diagnostic tumor imaging. Among these quinazoline EGFR-TK inhibitors, PD153035 has a very high inhibitory potency. The ParkeDavis Institute group and Tsou et al. have reported various structure-activity relationships of quinazoline derivatives [26, [28] [29] [30] [31] [32] [33] . From their results, it was thought that various modifications of the quinazoline structure to provide a radiopharmaceutical would be possible. Thus, PD 153035 was selected as a lead compound for development of a new EGFR-TK diagnostic agent. We have previously reported radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) as a phenoxyquinazoline derivative that has good characteristics for an EGFR-TK imaging ligand. In this study, our aim was to develop a radiopharmaceutical superior to radioiodinated PHY for tumor diagnoses that provided high tumor accumulation and selective interaction with the target molecule. On the basis of previous work in the development of various radiopharmaceuticals, several new phenoxyquinazoline derivatives with various side chains introduced on to the 6th position of the quinazoline were designed. Six phenoxyquinazoline derivatives were easily synthesized from the key compound 5 by reactions outlined in Scheme 1. Inhibitory potencies of these derivatives for EGFR-TK were measured ( Table 1 ). The IC 50 values were measured for the new inhibitors as well as for PD153035 and traditional EGFR-TK inhibitors as standards, and the new inhibitors were compared with these standard compounds to evaluate their inhibitory potency. The four quinazoline derivatives 6a-d were found to possess high inhibitory potency, while 6e and 6f displayed low inhibitory potency. In order to have high inhibitory potency against EGFR-TK, it is necessary that an inhibitor bind strongly to the ATP binding site. Thus, introduction of a hydrophilic side chain to the 6th position of the quinazoline providing a positive charge interaction was effective, particularly for hydrophilic side chains linked by a three carbon chain. These results were in agreement with previous structure-activity relationships [26, [28] [29] [30] [31] [32] [33] .
In initial screenings to assess the relative potential of the new radiolabeled quinazoline derivatives to act as diagnostic agents for tumor imaging by in vivo tumor uptake studies in A431 tumor-bearing mice (Fig. 2) 125 I]PYK from these peripheral organs was a desirable attribute for a radiopharmaceutical. The tumor uptake of various radiolabeled quinazoline derivatives as PET ligands has previously been reported. These ligands were observed to have relatively high tumor uptake 1 h post injection [14] [15] [16] ; however, they were also found to induce high radioactivity in peripheral tissues 1 h post 125 I]PYK has a high tumor-to-organ ratio 24 h after injection (Fig. 3) .
Selective interaction of [ 125 I]PYK with EGFR-TK on A431 tumor cell membranes was confirmed by pretreatment experiments with various EGFR-TK and other tyrosine kinase inhibitors. As shown in Fig. 4 (Fig. 5) . The reason about slight reduction of [ 125 I]PYK tumor accumulation by VEGFR inhibitor I was not clear, but it is known that the VEGFR inhibition causes various pharmacologic interactions such as decrease in tumor blood vessel permeability, vasoconstriction on tumor blood vessel [34, 35] . Accordingly, it was considered that this phenomenon might be caused by pharmacologic interactions on tumor blood vessel with VEGFR inhibitor I pretreatment.
In the binding assay of [ 125 I]PYK using A431 tumor cell membranes (Fig. 6) (Fig. 7) . Thus, [ 125 I]PYK might be useful as a diagnostic SPECT imaging agent for lung cancer.
Radioiodinated PYK showed high contrast imaging of tumors with EGFR-TK selectivity. Therefore, radioiodinated PYK-SPECT is expected to allow visualization of primary and metastatic tumor lesions that express active mutant EGFR-TK. Currently, we are exploring the feasibility of using radioiodinated PYK as a predictor for NSCLC therapy with gefitinib, and results of this study will be reported soon.
Conclusion
The iodinated quinazoline derivatives (6a-d) were found to have relatively high inhibitory potency against EGFR-TK. 
